retatrutide weight loss efficacy New Phase 3 data just dropped 👀 Eli Lilly's trial reported average approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Weight loss efficacy of selected

The Weight Watchers difference: At 6 months, our Med+ members on the GLP-1 Success Program lost 27 lbs, on average.^ ^Based on a 6-month clinical trial (n=180) of individuals who were enrolled between FebruaryApril 2024, with overweight or obesity taking semaglutide or tirzepatide for weight loss and related outcomes through the WW Clinic Program and participating in the GLP-1 companion nutrition program

Dose-by-dose weight loss in Phase 2 (NEJM) Phase 2 NEJM weight loss by dose, 24 and 48 weeks Dose 1 mg 24 weeks -7.2% 48 weeks -8.7% Dose 4 mg 24 weeks -12.9% 48 weeks -17.5% Dose 8 mg 24 weeks -15.7% 48 weeks -22.8% Dose 12 mg 24 weeks -17.5% 48 weeks -24.2% Dose Placebo 24 weeks -1.6% 48 weeks -2.1% Source: Jastreboff et al., NEJM 2023

If TRIUMPH-1 replicates these numbers, it will solidify retatrutide as the most effective pharmaceutical weight loss intervention ever studied

This type of research helps define receptor engagement, relative activity patterns, and mechanistic plausibility before broader interpretation

Its also important to have realistic expectations

Centralizing Patient Metrics for Faster Clinical Decisions Most people rely on scattered alarms and notes because they are familiar and low effort